Could Greater Washington be one of the big three in biotech beside other market leaders like, say, Boston?
That was certainly the rallying cry Monday as CEOs and a few hundred entrepreneurs, academics and government types packed into MedImmune's auditorium in Gaithersburg. MedImmune, the research and development arm of AstraZeneca (NYSE: AZN), was hosting the first Maryland Regional Biotech Forum to chart a course for elevating the region's reputation into the top three by 2023. The event was also hosted by the Tech Council of Maryland and BioHealth Innovation Inc.